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Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a
prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potential
role of the immunologic (homeostatic) environment aﬀecting NK-15 recovery and survival post-APHSCT has not been fully
studied. Therefore, we evaluate prospectively the cytokine proﬁle in 50 NHL patients treated with APHSCT. Patients with an
interleukin-15 (IL-15) ≥ 76.5pg/mL at day 15 post-APHSCT experienced superior OS and PFS compared with those who did not;
median OS; not reached versus 19.2 months, P<. 002; and median PFS; not reached versus 6.8 months, P<. 002, respectively.
IL-15 was found to correlate with (rs = 0.7, P<. 0001) NK-15. Multivariate analysis showed only NK-15 as a prognostic factor for
survival,suggestingthatthesurvivalbeneﬁtobservedbyIL-15ismostlikelymediatedbyenhancedNKcellrecoverypost-APHSCT.
1.Introduction
Day 15 absolute lymphocyte count (ALC-15) after autolo-
gous peripheral blood hematopoietic stem cell transplanta-
tion (APHSCT) has been shown to be a signiﬁcant predictor
for survival in multiple hematologic malignancies [1–9]a s
well as solid tumors [10–12]. Natural killer cells at day 15
(NK-15) have been identiﬁed as the key lymphocyte subset
in the ALC-15 that has a direct impact on survival post-
APHSCT [13]. In addition, the lymphocytes collected at
the same time with stem cells and infused to the patients
have a direct impact on ALC-15 and NK-15 post-APHSCT,
suggesting that the autograft can be viewed not only as the
means to achieve hematologic engraftment by the infusion
of stem cells but also as an adoptive immunotherapeutic
maneuver by infusion of an autograft absolute lymphocyte
count(A-ALC)aﬀectingimmunerecoveryandsurvivalpost-
APHSCT [14–16]. Adoptive cellular therapy depends on the
ability to optimally select the desired antigenic speciﬁcity
immune eﬀector cells and then induce cellular proliferation
while preserving the eﬀector function, engraftment, and
homing abilities of the lymphocytes [17]. The infusion of
A-ALC will provide the desired antigenic immune eﬀector
cells, but what factors to induce cellular proliferation while
preserving the eﬀector function, engraftment and homing
abilities of the lymphocytes to provide an eﬀective adoptive
cellular therapy in APHSCT are currently not well deﬁned.
Therefore, we set out to investigate the cytokine milieu at day
15 post-APHSCT to assess which cytokines aﬀect NK-15 and
the superior survival mediated by a faster NK-15 recovery
post-APHSCT. To achieve this goal the following endpoints
were evaluated in the study: (1) to assess a correlation
between cytokines and NK-15 post-APHSCT, (2) to assess
if interleukin-15 (IL-15) aﬀects survival post-APHSCT and
through which immune eﬀector cell, and (3) to identify a
source of IL-15 production at day 15 post-APHSCT.2 Clinical and Developmental Immunology
2.MaterialandMethods
2.1. Patient Population. Patients in the study were the same
patient group enrolled in prospective study from February
2002 to February 2007 to assess the role of ALC-15 and NK-
15 on survival post-APHSCT [13]. For this study 27 normal
controls donated blood samples to assess cytokines levels. All
patients signed written, informed consent to participate in
the study. Approval of the study was obtained from the Mayo
Clinic institutional review board and was in accordance with
U.S. federal regulations and the Declaration of Helsinki.
2.2. A-ALC, ALC-15, Monocytes, and NK-15. Autograft
absolute lymphocyte count (A-ALC) was determined as
previously reported: % collection lymphocytes × absolute
autograft white blood cell count/kilogram (kg) [18]. Auto-
graft monocyte count (A-mono) was determined as follows:
%c o l l e c t i o nm o n o c y t e s× absolute autograft white blood
cell count/kg. ALC-15 and monocytes at day 15 (mono-
15) were determined from the diﬀerential white blood cell
count obtained at day 15 post-APHSCT. NK-15, deﬁned
as CD16+/CD56+/CD3−, was according to manufacture’s
recommendations. Stained cells were then analyzed using
ﬂow cytometry (FACS callibur, Becton-Dickson, CA). Cells
were analyzed for the percentage of cells expressing said
antigens as well as average quantity of antigen expression
[13].
2.3. Cytokine Assay. Cytokines were measured using the
Bio-rad (Hercules, CA) human 27-plex system. Brieﬂy,
diluted human plasma was incubated for 30
  at room
temperature with washed beads. The beads are coated with
antibodies to the cytokines of interest. After incubation
with patient plasma the beads were washed and incu-
bated for 30
  with biotinylated 20 antibodies, followed by
incubation with PE-conjugated streptavidin. Quantization
of cytokines was performed on the Luminex 200 system
(Austin, TX). The cytokines tested included Interleukin (IL)-
1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10,
IL-12p70, IL-13, IL-15, IL-17, Eotaxin, ﬁbroblast growth
factor (FGF), granulocyte colony-stimulating factor (G-
CSF), granulocyte-macrophage colony-stimulating factor
(GM-CSF), interferon-gamma (IFN-G), interferon-gamma-
inducible protein 10 (IP-10), monocyte chemoattractant
protein-1 (MCP-1), macrophage inﬂammatory proteins 1a
and 1b (MIP-1a and MIP-1b), platelet-derived growth factor
(PDGF), RANTES, tumor-necrosis-factor-gamma (TNF-G),
and vascular endothelial growth factor (VEGF).
2.4. Prognostic Factors. Prognostic factors for post-APHSCT
OS and PFS evaluated in this study included cytokines, ALC-
15, NK-15, mono-15, international prognostic index (IPI)
factors, infused CD34, and disease status at transplant.
2.5. Peripheral Blood Stem Cell Collection. All patients
receivedG-CSF(10μg/kg)dailyfor5to7consecutivedaysby
subcutaneous injection. Once their peripheral blood CD34+
cell count was ≥10cells/μL, patients began daily apheresis
until they achieved a target of 5 × 106 CD34+ cells/kg. A
minimum target of 2 × 106 CD34+ cells/kg was required
for the patient to be considered for transplantation. Patients
wereassignedtotheBaxterAmicus(Baxter,healthcareCorp.,
Deerﬁeld, IL), Fenwal CS 3000 Plus (Baxter) or COBE
Spectra (Gambro BCT, Lakewood, CO) based on instrument
availability on the day of collection. Instrument setting used
for the collection procedures has previously been described
(ref). The number of apheresis collections was dependent
upon collection of an adequate number of CD34+ cells to
achieve hematologic engraftment post-APHSCT.
2.6. Conditioning Regimen. All patients received Carmustine
(BCNU) 300mg/m2 on day-6; etoposide 100mg·m2 twice a
day on days-5, -4, -3, and -2; and melphalan 140mg/m2 on
day-1 (BEAM). All patients received growth factor support
starting on day +6 with sargramostim 500μgd a i l yu n t i l
evidence of neutrophilic engraftment deﬁned as an absolute
neutrophil count (ANC) ≥ 500cells/μgo n3c o n s e c u t i v e
days.
2.7. Response and Survival. Response criteria were based on
the guidelines from the non-Hodgkin lymphoma (NHL)
international Workshop [19]. OS was measured from the
date of transplant to the date of death, or last follow-up.
PFS was deﬁned as the time from transplant to the time of
progression, relapse, death, or last follow-up.
2.8. Statistical Analysis. OS and PFS were analyzed using the
approach of Kaplan and Meier [20]. Diﬀerences between
survival curves were tested for statistical signiﬁcance using
the 2-tailed log-rank test. The Cox proportional hazard
model [21] was used for the univariate and multivariate
analysistoevaluatecytokines,NK-15,ALC-15,andmono-15
as a prognostic factor for post-APHSCT OS and PFS times.
In addition to the evaluation of cytokines (speciﬁcally
IL-15) and its prognostic signiﬁcance for OS and PFS, its
utility as a marker of NK-15 was also assessed. The choice
of optimal cutoﬀ of IL-15 was based on its utility as a
marker of NK-15 using Receiver operating characteristics
(ROCs) curves and area under the curve (AUC) as well as its
prognostic value for post-APHSCT OS and PFS. Prediction
of NK-15 was explored further in logistic regression models,
univariately assessing continuous and dichotomized values
of A-ALC, cytokines, and mono-15. χ2-tests were used
to determine relationships between categorical variables.
The Wilcoxon-rank test was used to determine associations
between continuous variable and categories, and Spearman
correlation coeﬃcients were used to evaluate associations for
continuous variables. Owing to multiple factors tested in the
univariate analysis, multiple comparison corrections using
Bonferroni correction procedure were applied declaring
statistical signiﬁcance at P<. 002 (α = 0.05/n, n = 27
cytokines).
The cut-oﬀ of ALC-15 ≥ 500cells/μL, A-ALC ≥ 0.5×109
lymphocytes/kg, and NK-15 ≥ 80cells/μL was based on data
from our previous studies [13–15].Clinical and Developmental Immunology 3
Table 1: Baseline characteristics of the cohort.
Characteristics n (%) Median Range
Age at transplant, years 50 (100%) 57.5 (23–73)
Sex
Female 17 (34%)
Male 33 (66%)
Lymphoma type
DLBCL 34 (68%)
Mantle cell 10 (20%)
T-cell 5 (10%)
Follicular 1 (2%)
Prognostic factors at diagnosis
Extra nodal sites
0 33 (66%)
1 15 (30%)
22 ( 4 % )
LDH (U/L) 50 (100%) 209 (150–1515)
Performance status
0 31 (62%)
1 17 (34%)
22 ( 4 % )
Stage
I 6 (12%)
II 5 (10%)
III 8 (16%)
IV 31 (62%)
IPI score
Age at transplant, years
≥60 23 (46%)
<60 27 (56%)
LDH
Normal 21 (42%)
Abnormal 29 (58%)
Extra nodal sites
≥22 ( 4 % )
<2 48 (96%)
Performance status
≥22 ( 4 % )
<2 48 (96%)
Stage
I/II 11 (22%)
III/IV 39 (78%)
Infused CD34 cells × 106/kg 50 (100%) 4.68 (2.03–8.56)
Infused A-ALC × 109 lymphocytes/kg 50 (100%) 0.55 (0.08–1.5)
ALC-15 cells/μL 50 (100%) 670 (2.0–4,500)
NK-15 cells/μL 50 (100%) 103 (10–999)
Mono-15 cells/μL 50 (100%) 860 (2.0–4,500)
Infused A-mono × 109 monocytes/kg 50 (100%) 0.58 (0.08–1.5)
A-ALC: autograft, absolute lymphocyte count; ALC-15: absolute lymphocyte count at day 15 post transplant; A-mono: autograft absolute monocyte count;
DLBCL: diﬀuse large B-cell lymphoma; IPI: International prognostic index; LDH: lactate dehydrogenase; Mono-15: absolute monocyte count at day 15 post
transplant; NK-15: absolute natural killer cell count at day 15 post transplant.4 Clinical and Developmental Immunology
Table 2: Cytokines levels comparison between normal volunteers, before transplantation, and at day 15 after transplantation.
Cytokines Normal Pretransplant Day 15 post
transplant
P-value Normal
versus
Pretransplant
P-value Normal
versus Day 15
post transplant
P-value Pre
versus Day
15 post
transplant
Median
(25th-75th
quartiles)
Median
(25th-75th
quartiles)
Median
(25th-75th
quartiles)
IL-1b 3.59 (2.32–5.55) 4.72 (3.48–7.79) 2.99 (1.3–8.11) .5 .8 .1
IL-1ra 120.12
(90.59–287.77)
356.56
(228.95–662.87)
283.33
(142.52–434.73) <.0001 <.0001 .01
IL-2 0 (0–56.12) 4.24 (0–23.87) 0 (0–7.89) .01 .7 <.0004
IL-4 3.09 (2.09–3.99) 3.95 (3.33–5.43) 2.12 (1.25–3.63) .6 .7 .02
IL-5 0.92 (0.69–1.67) 2.82 (1.79–3.96) 4.3 (2.93–13.75) <.0001 <.0001 .01
IL-6 0 (0–2.14) 11.78 (5.6–21.05) 24.48
(9.84–48.72) <.0001 <.0001 .01
IL-7 24.64
(13.59–39.08)
21.99
(16.85–39.95)
15.66
(5.77–26.61) .04 .007 .02
IL-8 2.57 (0.35–7.71) 30.89
(19.91–97.72)
36.67
(27.02–71.78) <.0001 <.0001 .2
IL-9 4.09 (0–68.28) 40.18
(4.93–91.22) 27.58 (8.29–64) .04 .04 .003
IL-10 1.97 (1.24–3.84) 4.91 (3.91–8.16) 8.94 (5.91–13.61) .01 <.0001 <.002
IL-12p70 6.7 (2.52–16.35) 15.27
(7.29–29.68) 7.61 (4.45–12.93) <.0006 .2 <.0004
IL-13 2.93 (1.33–4.17) 2.49 (1.71–5.26) 1.46 (0.56–2.31) .02 .5 <.002
IL-15 0 (0–0) 8.75 (0.07–110.5) 76.5 (5.4–219.22) <.0001 <.0001 <.0001
IL-17 10.62 (0–30.66) 18.43
(4.33–49.92) 7.08 (0–17.14) .01 .2 <.0001
Eotaxin 49.39
(41.43–76.41)
68.18
(42.26–104.04)
73.76
(44.96–108.87) .02 <.0001 .6
FGF 0 (0–0) 0 (0–84.64) 0 (0–13.07) .7 .8 .7
G-CSF 989 (385–1243) 83.08
(60.01–124.8)
67.48
(45.74–93.55) <.0001 <.0001 <.0001
GM-CSF 161.74
(32.26–1142.8)
80.99
(41.13–173.59)
63.75
(25.4–164.6) .01 <.0001 <.002
IFN-G 142.49
(87.71–264.05)
125.06
(78.04–193.52)
65.65
(28.81–86.42) .03 <.0009 <.0001
IP-10 245.22
(150.9–326.4)
915.6
(585.98–1783.83)
1440.53
(102.2–3067.40) <.0001 <.0001 <.0001
MCP-1 41.3 (0–90.25) 86.34
(33.83–146.48)
120.43
(54.46–209.55) .02 <.0001 .008
MIP-1a 7.4 (4.58–10.52) 12.9 (8.62–31.7) 8.56 (5.35–1363) <.001 .7 <.001
MIP-1b 51.23
(21.15–106.98)
97.36
(57.01–256.38)
104.34
(63.59–179.76) <.002 <.0001 .6
PDGF 1260.24
(805.22–2289.82)
2071.16
(1060.34–
3485.72)
423.71
(112.94–697.84) <.0001 <.0001 <.0001
RANTES 2650.98
(1584.55–4500) 2600 (2600–3000) 2302.37
(297.92–1072.83) .7 .1 <.001
TNF-G 0.74 (0–188.99) 70.48
(52.82–132.48)
32.06
(23.37–82.85) .02 .07 <.0001
VEGF 23.13 (12–55.42) 77.38
(28.42–104.34)
36.52
(10.28–91.85) <.0007 <.002 <.0001
Interleukin (IL)-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, Eotaxin, ﬁbroblast growth factor (FGF), granulocyte
colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma (IFN-G), interferon-gamma-inducible
protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inﬂammatory proteins 1a and 1b (MIP-1a and MIP-1b), platelet-derived
growth factor (PDGF), RANTES, tumor-necrosis-factor-gamma (TNF-G), and vascular endothelial growth factor (VEGF).Clinical and Developmental Immunology 5
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Figure 1: Scatterplot comparing IL-15 and NK-15 at day 15 post-APHSCT. Strong positive correlation was identiﬁed between IL-15 and
NK-15post-APHSCT(Spearmancorrelationrhofactor,rs = 0.7,P<. 0001).Only11patientshadIL-15levelhigherthan500pg/mL.Torule
out the possibility that these 11 patients made skewed the data resulting in the strong correlation between IL-15 and NK-15, we truncated
and analyzed the data for the 39 patients that had IL-15 levels between 0 and 500pg/mL. A strong positive correlation was still observed
between IL-15 and NK-15 (Spearman correlation rho factor, rs = 0.6, P<. 0002).
3. Results
3.1. Patient Characteristics. The median age at the time of
transplant for this cohort of 50 NHL patients was 57.7 years
(range: 23–73). Baseline characteristics for the patients are
described on Table 1. No patients were lost to follow-up. The
updated median follow-up for the cohort was 25.2 months
(range: 6–80.8 months). By the time of this analysis 25
patients(50%)hadevidenceofrelapseand18patients(36%)
had died. The transplant-related mortality for the cohort
was only 2% (1 of 50). One patient died of an intracranial
bleed, the rest because of progressive lymphoma. No patient
received ﬂudarabine-based regimens prior to APHSCT.
Table 2 shows the cytokine levels comparison between
normal volunteers and the cohort of patients before APH-
SCT and at day 15 post-APHSCT. The following cytokines
showed increased levels at day 15 post-APHSCT compared
with normal volunteers and before APHSCT: IL-5, IL-6, IL-
8,IL-10,IL-15,IP-10,MCP-1,andMIP-1b.Nosargramostim
was administered on day 15 post-APHSCT during research
blood collection for the study as all patients engrafted their
neutrophils prior to day 15 post-APHSCT.
3.2. IL-15 and NK-15. We previously reported that NK-15
is the key lymphocyte subset at day 15 aﬀecting survival
post-APHSCT. Thus we set out to investigate which cytokine
aﬀects NK-15 recovery post-APHSCT. Table 3 shows the
cytokine univariate analysis for correlation with NK-15.
IL-15 and ﬁbroblast growth factor (FGF) were strongly
correlated with NK-15. We also published that A-ALC
aﬀected NK-15 recovery. In logistic regression analysis, both
A-ALC (P<. 001) and IL-15 (P<. 002) retained their ability
to aﬀect NK-15 recovery post-APHSCT. IL-15 was found to
be both a strong predictor for area under the curve (AUC =
0.87, P<. 002) and strongly correlated with (rs = 0.7,
P<. 0001) NK-15. Figure 1 shows the scatter plot for IL-
15 and NK-15. Only 11 patients had IL-15 level higher than
500pg/mL. To rule out the possibility that these 11 patients
made skewed the data resulting in the strong correlation6 Clinical and Developmental Immunology
Table 3: Univariate analysis of the correlation between cytokines
and NK-15.
Cytokines Spearman (rho) correlation P-value
IL-1b 0.17 .2
IL-1ra 0.09 .5
IL-2 0.06 .7
IL-4 0.2 .1
IL-5 0.2 .2
IL-6 0.1 .3
IL-7 0.06 .6
IL-8 0.2 .1
IL-9 0.2 .1
IL-10 −0.2 .3
IL-12p70 0.1 .4
IL-13 0.1 .5
IL-15 0.7 <.0001
IL-17 0.1 .4
Eotaxin 0.1 .3
FGF 0.6 <.0001
G-GSF 0.1 .3
GM-CSF 0.1 .4
IFN-G 0.2 .2
IP-10 0.1 .4
MCP-1 0.06 .7
MIP-1a 0.2 .2
MIP-1b 0.2 .2
PDGF 0.2 .1
RANTES 0.06 .7
TNF-α 0.3 .06
VEGF 0.2 .2
Interleukin (IL)-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-
12p70, IL-13, IL-15, IL-17, Eotaxin, ﬁbroblast growth factor (FGF), granu-
locyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), interferon-gamma (IFN-G), interferon-
gamma-inducible protein 10 (IP-10), monocyte chemoattractant protein-
1 (MCP-1), macrophage inﬂammatory proteins 1a and 1b (MIP-1a and
MIP-1b),platelet-derivedgrowthfactor(PDGF),RANTES,tumor-necrosis-
factor-gamma (TNF-G), and vascular endothelial growth factor (VEGF).
between IL-15 and NK-15, we truncated and analyzed the
data for the 39 patients that had IL-15 levels between 0 and
500pg/mL.WestillobservedastrongcorrelationbetweenIL-
15 and NK-15 (rs = 0.6, P<. 0002). If we dichotomized
the NK-15, patients with an NK-15 ≥ 80cells/μLh a dh i g h e r
levels of IL-15 compared with those who did not (median
IL-15 of 155pg/mL versus 8.89pg/mL, P<. 002) (Figure 2).
3.3. Cytokines and Survival Post-APHSCT. Table 4 shows the
cytokines univariate analysis for survival post-APHSCT. The
cytokines were evaluated as continuous variables. IL-15 at
day 15 post-APHSCT was the only cytokine that was statis-
tically signiﬁcant for OS. IL-15 and PDGF were statistically
signiﬁcantforPFS.InthemultivariateanalysisforPFS,IL-15
was the only cytokine that remained statistically signiﬁcant
(IL-15: HR = 0.950; 95% CI = 0.824–0.978, P<. 002;
PDGF: HR = 1.020; 95% CI = 1.010–1.058, P = .02).
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Figure 2: Box plot comparing the IL-15 levels at day 15 post-
APHSCT between patients with an NK-15 ≥ 80cells/μL and NK-
15 < 80cells/μL. Patients with a NK-15 ≥ 80cells/μL had a higher
IL-15 levels (median of 155pg/mL) compared with patients with
aNK-15 < 80cells/μL( m e d i a no f8 . 8 9p g / m L )( P<. 002) at day 15
post-APHSCT.
A cut-oﬀ of 76.5pg/mL for IL-15 was supported by
being the median value of the data as well as it yielded the
greatestdiﬀerential in survival based on χ2 values analyzed at
diﬀerent cutoﬀ points (between the 25th and 75th quartiles)
from the log-rank tests. Patients with an IL-15 ≥ 76.5pg/mL
(n = 25) experienced superior OS (Figure 3(a))a n dP F S
(Figure 3(b)) compared with those who did not (n = 25);
median OS; not reached versus 19.2 months, 3 years OS rates
of 79% versus 47%, P<. 002; and median PFS; not reached
versus 6.8 months, 3 years PFS rates of 64% versus 31%,
P<. 002, respectively.
Inordertominimizeuncontrolledfactorsthatcouldhave
aﬀected IL-15 levels post-APHSCT, we analyzed patients
characteristics based on IL-15 ≥ 76.5pg/mL versus an IL-
15 < 76.5pg/mL (Table 5). We also analyzed if the pre-
transplant IL-15 levels were associated with day 15 post-
APHSCT IL-15 levels. We found a positive correlation
between pre- and post-APHSCT IL-15 levels (r = 0.6, P<
.0001).
To assess the role on survival of NK-15 and IL-15, we
categorized the patients into 4 groups: group I was patients
with an NK-15 ≥ 80cells/μL and IL-15 ≥ 76.5pg/mL; group
II was NK-15 ≥ 80cells/μL and IL-15 < 76.5pg/mL; group
III was NK-15 < 80cells/μL and IL-15 ≥ 76.5pg/mL; group
IV was NK-15 < 80cells/μL and IL-15 < 76.5pg/mL. We
observed worsening PFS in patients with progressing low
NK-15 and IL-15 levels compared with patients with high
NK-15 and IL-15 levels (3 years PFS rates for group I was
68%; group II was 49%; group III was 33%; group IV was
0%) (Figure 4). In the multivariate analysis comparing NK-
15 and IL-15 for OS and PFS, NK-15 truncated IL-15 (OS;
HR = 0.32, P = .02; and PFS: HR = 0.33, P = .01).Clinical and Developmental Immunology 7
Table 4: Univariate analysis for overall and progression-free survival.
Cytokines Overall survival P-value Progression-free survival P-value
IL-1b .08 .1
IL-1ra .2 .4
IL-2 .09 .1
IL-4 .03 .02
IL-5 .8 .3
IL-6 .07 .08
IL-7 .06 .06
IL-8 .01 .04
IL-9 .1 .2
IL-10 .02 .04
IL-12p70 .06 .06
IL-13 .06 .06
IL-15 <.0001 <.001
IL-17 .09 .1
Eotaxin .4 .02
FGF .2 .3
G-CSF .06 .06
GM-CSF .06 .06
IFN-G .04 .06
IP-10 .4 .5
MCP-1 .1 .2
MIP-1a .008 .008
MIP-1b .07 .1
PDGF .004 <.002
RANTES .6 .7
TNF-α .007 .006
VEGF .4 .3
Age ≥ 60 .16 .06
A-ALC .01 .004
ALC-15 <.0004 <.0001
CD34 .3 .8
Disease status at transplant: complete remission .11 .1
Extra nodal sites ≥ 2. 4 6 . 8
LDH; abnormal .3 .2
Mono-15 <.001 <.002
NK-15 <.0002 <.0002
PS > 1. 2 4 . 8 1
Stage III/IV .2 .28
Interleukin (IL)-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, Eotaxin, ﬁbroblast growth factor (FGF), granulocyte
colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma (IFN-G), interferon-gamma-inducible
protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inﬂammatory proteins 1a and 1b (MIP-1a and MIP-1b), platelet-derived
growth factor (PDGF), RANTES, tumor-necrosis-factor-gamma (TNF-G), vascular endothelial growth factor (VEGF), autograft absolute lymphocyte count
(A-ALC), absolute lymphocyte count at day 15 post transplant (ALC-15), lactate dehydrogenase (LDH), absolute monocyte count at day 15 post transplant
(Mono-15), natural killer cells at day 15 post transplant (NK-15), and performance status (PS).
3.3.1. Source of IL-15 at Day 15 Post-APHSCT (Mono-
cytes/Macrophages). T h em o n o c y t i c / m a c r o p h a g es y s t e mh a s
been reported as a source of IL-15. Thus, we set out to
investigate that the monocytic count at day 15 (mono-15)
post-APHSCT aﬀects IL-15 levels. We identiﬁed a good
correlationbetweenIL-15andmono-15(rs = 0.8,P<. 0001)
(Figure 5). We also identiﬁed a good correlation between
NK-15 and mono-15 (rs = 0.54, P<. 0001). However,
in logistic regression analysis, IL-15 and A-ALC remained
statistical signiﬁcant as sources of NK-15 and truncated
mono-15 (P = .1) (Table 6), suggesting that the mono-15
ability to aﬀect NK-15 is mediated by the production of IL-
15. Mono-15 was also associated with OS (P<. 001) and PFS
(P<. 002) (Figures 6(a) and 6(b)). However, in multivariate8 Clinical and Developmental Immunology
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Figure 3: (a) Overall survival (OS) of patients with an interleukin-15 (IL-15) ≥ 76.5pg/mL versus patients with an IL-15 < 76.5pg/mL.
The median OS was not reached in the group of patients with an IL-15 ≥ 76.5pg/mL and 19.2 months with the group of patients with an
IL-15, 76.5pg/mL. The OS rates at 3 years were 79% and 47%, respectively (P<. 002). (b) Progression-free survival (PFS) of patients with an
interleukin-15 (IL-15) ≥ 76.5pg/mL versus patients with an IL-15 < 76.5pg/mL. The median PFS was not reached in the group of patients
with an IL-15 ≥ 76.5pg/mL and 6.8 months with the group of patients with an IL-15, 76.5pg/mL. The PFS rates at 3 years were 64% and
31%, respectively (P<. 002).
analysis, NK-15 remained the only statical prognostic factor
for survival compared with mono-15 (OS, P = .9; PFS, P =
.9), or ALC-15 (OS, P = .8; PFS, P = .2) (Table 7). To assess
the source of mono-15 recovery, we analyzed the number of
A-mono infused and found a good correlation between A-
mono and mono-15 (rs = 0.5, P<. 001). In addition, we
identiﬁed a positive correlation between A-mono and NK-15
(r = 0.4, P<. 008) and between A-mono and IL-15 at day 15
post-APHSCT (r = 0.3, P<. 04).
4. Discussion
ALC-15 ≥ 500cells/μL is a prognostic factor for survival
post-APHSCT. NK-15 is the key lymphocyte subset of
ALC-15 contributing to the superior clinical outcomes
that observed post-APHSCT. ALC-15 and NK-15 recovery
depends on the infused A-ALC, suggesting the new concept
that the autograft used to infuse stem cells in APHSCT can
be used also as an adoptive immunotherapeutic maneuver
to enhance immune recovery, translating into better clinical
outcomes post-APHSCT. However, for an adoptive cellular
therapy to be eﬀective, it requires cellular proliferation
while preserving the eﬀector function. We have previously
published that NK cells at two weeks post-APHSCT are
functionallyactive[22].Thus,westudiedthecytokinemilieu
at day 15 post-APHSCT to assess its interaction with NK-15
recovery and survival post-APHSCT.
Our cytokine proﬁle at day 15 post-APHSCT is similar
to what has been previously reported in autologous stem
cell transplantation. [23, 24]. However, to our knowledge
this is the ﬁrst study looking at the role of IL-15 on NK-
15 recovery and survival post-APHSCT. IL-15 was the only
cytokine at day 15 post-APHSCT that was associated with
survival post-transplant. IL-15 has been reported to support
the homeostasis of IL-2/IL-15Rβ expressing memory CD8+
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Figure 4: Progression-free survival based on categorized subset
analysis of NK-15 and IL-15 levels. Group I was patients with an
NK-15 ≥ 80cells/μL and IL-15 ≥ 76.5pg/mL; group II was NK-
15 ≥ 80cells/μL and IL-15 < 76.5pg/mL; group III was NK-15
< 80cells/μL and IL-15 ≥ 76.5pg/mL; group IV was NK-15 <
80cells/μL and IL-15 < 76.5pg/mL. The 3-year PFS rate for group I
was 68%; group II was 49%; group III was 33%; group IV was 0%.
T cells and NK cells via transpresentation of IL-15 by IL-
15Rα expressing cells [25, 26]. We previously reported that
NK-15 is the key lymphocyte subset of ALC-15 aﬀecting
survival post-APHSCT [13]. Since IL-15 has been associated
with NK cells homeostasis and diﬀerentiation, we set out
to identify if there was an association between IL-15 and
NK-15 post-APHSCT. We identiﬁed a strong correlation
between IL-15 and NK-15 as a continuous or dichotomized
variable. Our ﬁnding is similar to what has been reportedClinical and Developmental Immunology 9
Table 5: Patients baseline characteristics based on IL-15 ≥ 76.5pg/mL versus IL-15 < 76.5pg/mL.
Characteristics IL-15 < 76.5pg/mL (n = 25) IL-15 ≥ 76.5pg/mL (n = 25) P-value
Age at transplant, years: median (range) 62 (44–73) 54 (23–71) .02
Gender .2
Female 6 11
Male 19 14
Lymphoma type .7
DLBCL 17 17
Mantle cell 5 5
T-cell 3 2
Follicular 0 1
Prognostic factors at diagnosis
Extranodal disease .2
01 5 1 7
18 7
22 0
LDH (U/L), median (range) 222 (150–550) 200 (170–1515) .5
Performance status .1
01 2 1 9
11 2 5
21 1
Stage .3
I2 4
II 1 4
III 4 4
IV 18 13
IPI score
Age at transplant, years .1
≥60 15 8
<60 10 17
Extranodal sites .5
≥22 0
<22 3 2 5
LDH (U/L) .3
Abnormal 13 8
Normal 12 17
Performance status .9
≥21 1
<22 4 2 4
Stage .2
I/II 3 8
III/IV 22 17
IPI index .03
01 4
14 1 1
21 5 7
35 3
Disease status prior to transplant .5
CR 6 9
PR 19 1610 Clinical and Developmental Immunology
Table 5: Continued.
Characteristics IL-15 < 76.5pg/mL (n = 25) IL-15 ≥ 76.5pg/mL (n = 25) P-value
Infused CD34 cells × 106/kg; median (range) 5.17 (2.2–8.56) 4.4 (2.03–8.1) .2
ALC-15 cells/μL: median (range) 0.65 (0.02–1.91) 0.68 (0.1–4.5) .2
ALC-15 cells/μL .2
≥500 15 20
<500 10 5
Infused A-ALC × 109 lymphocytes/kg: median (range) 0.55 (0.02–1.66) 0.63 (0.14–1.66) .1
Infused A-ALC .2
≥0.5 × 109 lymphocytes/kg 14 19
<0.5 ×109 lymphocytes/kg 11 6
Infused A-mono × 109 monocytes/kg: median (range) 0.57 (0.06–1.5) 0.65 (0.26–1.5) .3
Mono-15cells/μL: median (range) 0.85 (0.02–2) 0.86 (0.06–4.5) .8
NK-15cells/μL: median (range) 98 (10–744) 130 (12–999) .8
A-ALC:autograft,absolutelymphocytecount;ALC-15:absolutelymphocytecountatday15posttransplant;A-mono:autograftabsolutemonocytecount;CR:
complete remission; DLBCL: diﬀuse large B-cell lymphoma; IPI: International prognostic index; LDH: lactate dehydrogenase; Mono-15: absolute monocyte
count at day 15 post transplant; PR: partial remission; NK-15: absolute natural killer cell count at day 15 post transplant.
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Figure 5:ScatterplotcomparingIL-15andmono-15atday15post-
APHSCT. Strong positive correlation was identiﬁed between IL-15
and mono-15 post-APHSCT(Spearman correlation rhofactor, rs =
0.8, P<. 0001).
in allogeneic stem cell transplantation, where faster NK
cell recovery early post allogeneic stem cell transplantation
is associated with elevated IL-15 levels [27]. Despite the
small number of patients, patients with higher NK-15
and IL-15 levels experienced better PFS compared with
patients with progressing lower NK-15 and IL-15 levels.
Multivariate analysis showed that NK-15 truncated IL-15
levels, suggesting that the possibility that the survival beneﬁt
observed by IL-15 is mediated by enhanced NK cell recovery
post-APHSCT. Another factor associated with NK-15 and
previously reported was A-ALC. A-ALC was an independent
factor aﬀecting NK-15 recovery when compared with IL-15,
suggesting that A-ALC, as an adoptive cellular therapy, pro-
vides a direct inﬂux of immune eﬀector cells (i.e., NK cells),
while IL-15 helps to sustain the proliferation of NK cells.
Table 6: Logistic regression analysis of factors aﬀecting NK-15
recovery post-APHSCT.
Factors Estimate Standard
Error χ2 P-value
A-ALC 20.6 79.9 18.2 <.0001
IL-15 at day 15
post-APHSCT 19.9 85.6 8.3 <.004
Mono-15 1.32 0.75 1.7 .1
A-ALC:autograft,absolutelymphocytecount;APHSCT:autologousperiph-
eral blood hematopoietic stem cell transplantation; IL-15: interleukin-15;
Mono-15:absolutemonocytecountatday15posttransplant;χ2:chisquare.
Table 7: Multivariate analysis for overall and progression-free
survival.
Factors Overall survival Progression-free survival
RR 95% CI P-value RR 95% CI P-value
ALC-15 0.656 0.128–2.657 .8 0.628 0.152–2.107 .2
Mono-15 1.125 0.316–3.317 .9 1.060 0.374–2.637 .9
NK-15 0.176 0.062–0.797 <.006 0.188 0.057–0.593 <.002
ALC-15: absolute lymphocyte count at day 15 post transplant; Mono-15:
absolute monocyte count at day 15 post transplant; and NK-15: natural
killer cells at day 15 post transplant.
Due to the apparent role of IL-15 on NK-15 recovery,
we set out to investigate possible sources of IL-15 at day
15 post-APHSCT. Monocytes have been implicated as a
source of IL-15 [28]. Thus, we studied the monocyte
recovery at day 15 (mono-15) post-APHSCT, as a surrogate
marker of IL-15 production, and its correlation with IL-15
levels. We identiﬁed a strong correlation between mono-
15 and IL-15 at day 15 post-APHSCT. We also found
an association between mono-15 and NK-15. However, a
multivariate analysis showed IL-15 and not mono-15 as the
factor aﬀecting NK-15 recovery, suggesting that the eﬀectClinical and Developmental Immunology 11
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Figure 6: (a) Overall survival (OS) of patients with a mono-15 ≥ 450cells/μL versus patients with a mono-15 < 450cells/μL. The median
OS was not reached in the group of patients with a mono-15 ≥ 450cells/μL and 12.6 months with the group of patients with a mono-15
< 450cells/μL. The OS rates at 3 years were 70% and 42%, respectively (P<. 001). (b) Progression-free survival (PFS) of patients with a
mono-15 ≥ 450cells/μL versus patients with a mono-15 < 450cells/μL. The median PFS was not reached in the group of patients with a
mono-15 ≥ 450cells/μL and 4.5 months with the group of patients with a mono-15 < 450cells/μL. The PFS rates at 3 years were 71% and
33%, respectively (P<. 002).
on NK-15 recovery by mono-15 is most likely mediated
by the production of IL-15 by mono-15. Another possible
source of IL-15 is from dendritic cells [28]. Recently, it
has been reported that the infusion of autograft dendritic
cells as well as their recovery post transplant aﬀects survival
in lymphoma patients treated with APHSCT [29]. It is
reasonable to hypothesize that the survival beneﬁt from the
infusion and recovery of dendritic cells post-APHSCT could
also be related due to the production of IL-15 by dendritic
cells activating NK cells. However, it is important to mention
otherfactorsthatcouldaﬀecttheIL-15levelsduringtheperi-
transplant period including (1) depletion of the lymphoid
populations that normally consumed circulating IL-15 due
to the conditioning regimens [27], or (2) response to the
inﬂammatory environment triggered by the conditioning
regimens [30, 31].
Alimitationofthestudyisthateventhoughweidentiﬁed
prospectivelya correlationbetweenIL-15and NK-15 leading
to better survival post-APHSCT, it does not prove causation.
This limitation is based on the fact that this is a prospective
correlative study which might not have controlled for factors
that could have aﬀect IL-15 levels post-APHSCT such as
(1) prior treatments before APHSCT and ﬂudarabine-based
regimens that could have aﬀected A-ALC collection, ALC-
15 recovery (i.e., NK-15), as well as mono-15 recovery post-
APHSCT; and (2) the use of sargramostim aﬀecting cytokine
production. However, patient’s baseline characteristics were
overallbalancedregardlessifIL-15levelswereequal/aboveor
below 76.5pg/mL. The positive correlation between pre- and
post-APHSCTIL-15levelssuggeststhatthepretransplantIL-
15 levels might help to anticipate prognosis after APHSCT.
We hope that our ongoing Phase III randomized double-
blind trial assessing if higher infusion of A-ALC translates
into faster immune recovery and thus better survival post-
APHSCT will address the relationship between IL-15 and
NK cells as ancillary immunologic studies will be performed
on this trial. In this trial none of the patients will receive
sargramostim post-APHSCT. The premise of this phase III
study is based on the fact that we have shown that by manip-
ulating the mononuclear cell band during the centrifugation
process of the apheresis machine, we can collect higher
numbers of na¨ ıve T-cells and NK cells with direct impact on
immune recovery post-APHSCT [32]. In this study, patients
will be randomized to collect stem cells with the standard
apheresis machine settings versus the modiﬁed apheresis
machine settings, aiming at collecting more immune eﬀector
cells. Similarly, the results of the current study suggest that
enriching the autograft with monocytes might also have a
directimpactonNK-15recoveryandsurvivalpost-APHSCT.
This hypothesis will be tested in the phase III study.
Based on the results of this study it appears that
NK-15 recovery (the key lymphocyte subset of ALC-15
aﬀecting survival post-APHSCT) depends on the adoptive
infusion from A-ALC and the homeostatic/proliferative
eﬀect of IL-15. Monocytes/dendritic cells appear to mediate
an NK cell supportive “homeostatic environment” poten-
tially facilitating NK cells engraftment mediated by IL-
15 following-APHSCT, ultimately leading to a therapeutic12 Clinical and Developmental Immunology
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Figure 7: Schematic representation of autologous graft-versus-
tumor eﬀect (hypothesis).
autologous graft-versus-tumor eﬀect (Figure 7). Evaluation
of this hypothesis is currently underway on our Phase III
study (Study ID: CDR0000577897, MAYO-MC0681).
In summary, this is the ﬁrst study showing the role IL-15
onsurvivalpost-APHSCTmostlikelybysupportingNKcells
engraftment. In addition, this study also shows monocytes
as possible source of IL-15, suggesting that the monocyte
countcanbeusedasasurrogatemarkertoassessthecytokine
milieu (speciﬁcally IL-15) post-APHSCT. Further studies are
warranted to understand the role of cytokines on survival
post-APHSCTtodevelopmoreeﬀectiveimmunotherapeutic
treatments in the APHSCT setting.
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